SEC Filings
Olema Cash Falls To $413.8 Million From $505.4 Million Ahead Of Pivotal Cancer Results
Research expenses rose to $67.6 million as Olema funded breast-cancer trials and prepared for potential commercialization.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Research expenses rose to $67.6 million as Olema funded breast-cancer trials and prepared for potential commercialization.
SEC Filings
The September-end position covered 3,595,632 common shares and was held through ordinary business activity.
SEC Filings
The holding covered 12,294,412 shares, while BioCryst raised its revenue outlook and pulled back from internal research.
SEC Filings
Research spending rose to $36.6 million as verekitug moved toward pivotal asthma and nasal-polyp trials.
SEC Filings
The reported holding covered 7,570,589 shares, with shared voting authority over 4,863,692.
SEC Filings
Taiho's lung-cancer combination application is now expected to be completed in November, rather than by year-end.
SEC Filings
The passive holding covered September 30, while the current-quarter earnings estimate fell to $1.70 per share from $1.78.
SEC Filings
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
SEC Filings
The company raised its annual revenue floor to $25 million, while unfilled orders fell 24% during the quarter.
SEC Filings
The reported position covered 1,810,255 shares, with voting authority shared over most of the holding.
SEC Filings
Initial ISEMBYLD shipments brought in $0.6 million, with first patient infusions in October and overseas regulatory reviews underway.
SEC Filings
Centrus's quarterly sales fell 26%, while management said contingent enrichment sales commitments reached $5.4 billion.